Richard M. Glickman

Biography

 Dr. Richard Glickman was a co-founder and CEO of Aspreva Pharmaceuticals. Under his leadership, Aspreva went public within 4 years from startup with an $80-million initial public offering, the largest in Canadian biotech history. Aspreva was acquired 6 years after its founding for nearly US$1 Bln in October 2007. Prior to Aspreva, Richard was the co-founder and CEO of StressGen Biotechnologies Corporation, where he grew the company from startup to a major biotechnology player with a market capitalization of over $500 million.   

Research Interest

 He was also the founder and a director of Ontario Molecular Diagnostics, which evolved into the largest molecular diagnostic laboratories in Canada. Richard also co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first licensed DNA-based forensic and paternity testing services in Canada. He has served on numerous biotechnology boards including roles as Chairman of Life Sciences B.C., Director of the Canadian Genetic Disease Network and a member of the federal government's National Biotechnology Advisory Committee. Richard received the Ernst & Young Entrepreneur of the Year Award in 2004; both Canada's and British Columbia's Top 40 under 40 Award for Entrepreneurs; and the BC Biotech Leadership Award in 2006. Richard currently serves as a director for a number of private and public biotechnology companies.